Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Galunisertib [700874-72-2]
Referencia T2510-10mg
embalaje : 10mg
Marca : TargetMol
Contact local distributor :
Teléfono : +1 850 650 7790
Galunisertib
Catalog No. T2510 CAS 700874-72-2
Synonyms: LY2157299
Galunisertib (LY2157299) is an orally available inhibitor of TGFβRI kinase (IC50: 56 nM) with potential antineoplastic activity.
All TargetMol products are for research or drug registration purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose in violation of laws and regulations.
Galunisertib, CAS 700874-72-2
| Pack Size | /USD | |
|---|---|---|
| 5 mg | In stock | |
| 10 mg | In stock | |
| 25 mg | In stock | |
| 50 mg | In stock | |
| 100 mg | In stock | |
| 200 mg | In stock | |
| 500 mg | In stock | |
| 1 g | In stock | |
| 1 mL * 10 mM (in DMSO) | In stock |
Select Batch 
Purity: 100%
Purity: 99.98%
Purity: 99.85%
Purity: 97.09%
Contact us for more batch information
| Description | Galunisertib (LY2157299) is an orally available inhibitor of TGFβRI kinase (IC50: 56 nM) with potential antineoplastic activity. |
| Targets&IC50 | TβRI:56 nM (cell free) |
| In vitro | The HCC cell lines were simultaneously exposed to 0.1, 1, 10, and 100 μM galunisertib (LY-2157299) with 5 μM sorafenib in presence of TGF-β for 72 hours. Galunisertib displayed a slight dose-dependent potentiation of sorafenib in SK-Sora, HepG2, and Hep3B cell lines but not in JHH6, SK-HEP1, and HuH7 cell lines [2]. Leukemic cells (K562) and marrow stromal cells (HS-5) were treated with TGF-β1 (20 ng/ml) in the presence and absence of LY-2157299 (5 μM) and assessed for SMAD2 phosphorylation by immunoblotting. LY-2157299 pretreatment (1 hr) led to attenuation of activation/phosphorylation of SMAD2 [3]. |
| In vivo | Mice transgenic for alb/TGF-β were treated with either LY-2157299 (100 mg/kg/d) or vehicle daily by gastric lavage for 14 days. Blood counts were done on the 14th day and revealed a significant rise in hematocrit after LY-2157299 treatment. The mice were sacrificed and bone marrow biopsies were immunostained with an antibody against phosphor-SMAD2. Representative sample shows inhibition of SMAD2 activation after LY-2157299 treatment [3]. After oral administration of 75 mg/kg, LY2157299 induced a 70% decrease in pSmad for both types of cell lines. The time at which pSmad recovered 80% of baseline was approximately 6 h after administration [4]. |
| Kinase Assay | Briefly, the assay was first done at 30°C for 4 h in a 96-well plate containing 2 ng/mL TGF-bR KD, 100 mM Hepes pH 7.5, 4 mM MgCl2, 0.2 mM MnCl2, 0.4 mM sodium orthovanadate, 2 mM DL-dithiothreitol, and 10mM ATP. After incubation, 50mL of Kinase-Glo plus reagent was added and further incubated at 25°C for 30 min. Subsequently, a 100mL aliquot of each reaction mixture was transferred to a black mictotiter plate and the luminescence was measured by a vector counter. The inhibitory activity IC50 was tested in duplicate for each sample [1]. |
| Cell Research | Cell survival was determined using the MTT assay. The conversion of yellow water-soluble tetrazolium MTT into purple insoluble formazan is catalyzed by mitochondrial dehydrogenases and used to estimate the number of viable cells. In brief, cells were seeded in 96-well tissue culture plates at a density of 2 × 103 cells/well. After drug exposure, cells were incubated with 0.4 mg/mL MTT for 4 hours at 37°C. After incubation, the supernatant was discarded, insoluble formazan precipitates were dissolved in 0.1 mL of DMSO, and the absorbance was measured at 560 nm by use of a microplate reader. Wells with untreated cells or with drug-containing medium without cells were used as positive and negative controls respectively. For proliferation assay, MTT assay was done daily to determine the number of viable cells in untreated control and galunisertib-treated group [2]. |
| Animal Research | Transgenic mice expressing a fusion gene (Alb/TGF) consisting of modified porcine TGF-β1 cDNA under the control of the regulatory elements of the mouse albumin gene (26) were used under animal institute approved protocol. Mice were given LY-2157299 at a dose of 100mg/kg/day in NaCMC/SLS/PVP/antifoam solution by gastric lavage using a curved 14 G needle. Blood counts were analyzed by the Advia machine. Mice femurs were flushed and bone marrows cells were used for clonogenic assays [3]. |
| Synonyms | LY2157299 |
| Molecular Weight | 369.42 |
| Formula | C22H19N5O |
| CAS No. | 700874-72-2 |
Storage
Solubility Information
DMSO: 50 mg/mL (135.35 mM)
Ethanol: Insoluble
References and Literature
1. Cong L, et al. Targeting the TGF-β receptor with kinase inhibitors for scleroderma therapy. Arch Pharm (Weinheim). 2014 Sep;347(9):609-15. 2. Serova M, et al. Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients. Oncotarget. 2015 Aug 28;6(25):21614-27. 3. Zhou L, et al. Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase. Cancer Res. 2011 Feb 1;71(3):955-63. 4. Bueno L, et al. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. Eur J Cancer. 2008 Jan;44(1):142-50. 5. Li W, Tibben M, Wang Y, et al. P‐glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF‐β signaling pathway inhibitor galunisertib[J]. International journal of cancer. 2020, 146(6): 1631-1642 6. Lu H H, Lin S Y, Weng R R, et al. Fucosyltransferase 4 shapes oncogenic glycoproteome to drive metastasis of lung adenocarcinoma[J]. EBioMedicine. 2020, 57: 102846 7. Mei Y, Jiang T, Zou Y, et al. Fucosyltransferase 4 shapes oncogenic glycoproteome to drive metastasis of lung adenocarcinoma[J]. EBioMedicine. 2020, 57: 102846. 8. Su Q, Fan M, Wang J, et al. Sanguinarine inhibits epithelial–mesenchymal transition via targeting HIF-1α/TGF-β feed-forward loop in hepatocellular carcinoma[J]. Cell Death & Disease. 2019, 10(12): 1-15.
Citations
1. Su Q, Fan M, Wang J, et al. Sanguinarine inhibits epithelial–mesenchymal transition via targeting HIF-1α/TGF-β feed-forward loop in hepatocellular carcinoma. Cell Death & Disease. 2019, 10(12): 1-15 2. Lu H H, Lin S Y, Roc Weng R, et al. Fucosyltransferase 4 shapes oncogenic glycoproteome to drive metastasis of lung adenocarcinoma. EBioMedicine. 2020, 57: 102846 3. Zhu M, Tang X, Gong Z, et al. TAD1822-7 induces ROS-mediated apoptosis of HER2 positive breast cancer by decreasing E-cadherin in an EphB4 dependent manner. Life Sciences. 2021: 119954 4. Li W, Tibben M, Wang Y, et al. P‐glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF‐β signaling pathway inhibitor galunisertib. International Journal of Cancer. 2020, 146(6): 1631-1642 5. Windhaber C, Heckl A, Csukovich G, et al.A matter of differentiation: equine enteroids as a model for the in vivo intestinal epithelium.Veterinary Research.2024, 55(1): 1-21.
Related compound libraries
This product is contained In the following compound libraries：
Inhibitor Library Drug Repurposing Compound Library Anti-Cancer Active Compound Library TGF-beta/Smad Compound Library Anti-Cancer Drug Library Kinase Inhibitor Library Anti-Cancer Clinical Compound Library Anti-Lung Cancer Compound Library Anti-Breast Cancer Compound Library Anti-Cancer Compound Library
Related Products
Related compounds with same targets
Dose Conversion
You can also refer to dose conversion for different animals. More
In vivo Formulation Calculator (Clear solution)
Step One: Enter information below
Dosage
mg/kg Average weight of animals
g Dosing volume per animal
ul Number of animals
Step Two: Enter the in vivo formulation
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL)，
Method for preparing in vivo formulation：Take μL DMSO master liquid, next add μL PEG300， mix and clarify, next add μL Tween 80，mix and clarify, next add μL ddH2O, mix and clarify.
Note:
Be sure to add the solvent(s) in order. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
Calculator
bottom
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Keywords
Galunisertib 700874-72-2 Stem Cells TGF-beta/Smad inhibit LY 2157299 LY2157299 Transforming growth factor beta receptors Inhibitor LY-2157299 TGF-β Receptor inhibitor